0001628280-24-000949.txt : 20240109 0001628280-24-000949.hdr.sgml : 20240109 20240109161004 ACCESSION NUMBER: 0001628280-24-000949 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marchio Albert N II CENTRAL INDEX KEY: 0001196054 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 24523366 MAIL ADDRESS: STREET 1: C/O FRESH TRACKS THERAPEUTICS, INC. STREET 2: 2000 CENTRAL AVENUE, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 FORMER NAME: FORMER CONFORMED NAME: MARCHIO ALBERT N II DATE OF NAME CHANGE: 20021003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fresh Tracks Therapeutics, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: Brickell Biotech, Inc. DATE OF NAME CHANGE: 20190830 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 4 1 wk-form4_1704834595.xml FORM 4 X0508 4 2023-12-28 0 0000819050 Fresh Tracks Therapeutics, Inc. FRTX 0001196054 Marchio Albert N II C/O FRESH TRACKS THERAPEUTICS, INC 2000 CENTRAL AVENUE, SUITE 100 BOULDER CO 80301 1 1 0 0 CEO and CFO 0 Restricted Stock Units 2023-12-28 4 D 0 1250 0.91 D Common Stock 1250 0 D Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment"). The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs. /s/ Griffin D. Foster, Attorney-in-Fact for Albert N. Marchio II (power of attorney previously filed) 2024-01-09